Patents by Inventor Mitchell Brigell

Mitchell Brigell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITON AND METHOD FOR PREVENTION AND TREATMENT OF CUTANEOUS RADIATION INJURY
    Publication number: 20240342114
    Abstract: Compositions and methods for treating cutaneous radiation injury (CRI), including radiation dermatitis, radiation proctopathy, or oral mucositis, employing one or more functional inhibitor of acid sphingomyelinase (FIASMA).
    Type: Application
    Filed: March 22, 2023
    Publication date: October 17, 2024
    Applicant: Rythera Therapeutics, Inc.
    Inventors: Reginald L. Hardy, Mitchell Brigell
  • Composition and method for prevention and treatment of radiation dermatitis
    Patent number: 11179353
    Abstract: A composition comprising at least one TCA or SSRI useful in a method for preventing or treating a skin disorder such as radiation dermatitis, and method of preventing, ameliorating, or treating the skin disorder by administering an effective amount of the TCA, e.g., amitriptyline or the SSRI, e.g., sertraline.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: November 23, 2021
    Inventors: Reginald L. Hardy, Mitchell Brigell
  • Composition and method for prevention and treatment of anorectal disorders
    Patent number: 11173111
    Abstract: A composition comprising at least one TCA useful in a method for treating an anorectal disorder, a rectal device and method of treating the anorectal disorder by anorectally administering an effective amount of the TCA, e.g. amitriptyline.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: November 16, 2021
    Assignee: Rythera Therapeutics, Inc.
    Inventors: Reginald L. Hardy, Mitchell Brigell
  • DOSING REGIMES FOR THE TREATMENT OF OCULAR VASCULAR DISEASE
    Publication number: 20130197016
    Abstract: The use of vascular endothelial growth factor receptor 2 inhibitors or a pharmaceutically acceptable salt thereof for the treatment of ocular vascular disease is provided. Dosing regimes, including once weekly administration, of certain VEGF-R2 inhibitors are provided which deliver therapeutically effective concentrations of the VEGF-R2 compounds in ocular tissues for at least one week for the treatment of ocular vascular disease.
    Type: Application
    Filed: October 25, 2011
    Publication date: August 1, 2013
    Inventors: Mitchell Brigell, Peter End, Vinayak Hosagrahara, Bruce D. Jaffee, Erik Meredith, Ronald Keith Newton, Stephen Poor, Yubin Qiu